This bill changes how Medicare Part D coinsurance is calculated for seniors. Starting in 2026, for drug costs above the deductible but below the out-of-pocket limit, coinsurance will be based on the drug's *net price* (the actual negotiated price after manufacturer discounts) instead of the list price. It directly affects Medicare Part D beneficiaries and prescription drug plans by requiring plans to use the net price when calculating these costs. The net price is defined as the discounted price reported in the Detailed DIR Report, excluding manufacturer discounts. This change aims to reduce out-of-pocket costs for seniors by aligning coinsurance with the lower price paid by the plan.
S 3019, the "No Big Blockbuster Bailouts Act," amends Medicare's drug price negotiation program to change how orphan drugs (treatments for rare diseases) are handled. It raises the revenue threshold from $200 million to $400 million before orphan drugs become subject to price negotiations under Medicare. This directly affects pharmaceutical companies developing drugs solely for rare diseases, as they will face price negotiations only if their annual U.S. revenue exceeds $400 million. The change applies to initial price negotiations starting January 1, 2028.
The PBM Price Transparency and Accountability Act requires pharmacy benefit managers (PBMs) to be more transparent about drug pricing and ensure accurate payments to pharmacies. It establishes national average drug acquisition cost benchmarks for Medicaid, prohibits PBMs from keeping excessive profits through "spread pricing," and mandates detailed reporting of drug pricing, rebates, and fees. The bill affects Medicaid programs, Medicare Part D plans, and the PBMs that negotiate drug prices on behalf of insurers. It includes enforcement mechanisms like civil penalties for non-compliance and requires PBMs to report detailed pricing information to the Secretary of Health and Human Services.
This bill amends FDA review procedures to prevent delays in generic drug approvals. It requires drug companies challenging generic applications to submit a petition to the FDA within 180 days of knowing the relevant information, rather than immediately filing lawsuits. The FDA must issue a final decision on such petitions within 151 days, and courts will automatically dismiss lawsuits that skip this step or miss the 180-day deadline. These changes directly affect pharmaceutical manufacturers seeking to challenge generic drug approvals or delay their market entry.
S 3064, the Relief of Chronic Pain Act of 2025, modifies Medicare Part D coverage to improve access to non-opioid treatments for specific chronic pain conditions. It requires Medicare plans to exempt qualifying non-opioid drugs (approved for conditions like diabetic neuropathy, fibromyalgia, or musculoskeletal pain) from deductibles and place them on the lowest cost-sharing tier starting in 2026. The bill also bans step therapy (requiring opioid use first) and prior authorization for these drugs. This directly affects Medicare beneficiaries with the listed chronic pain conditions who rely on these approved non-opioid medications.
This bill redefines certain health marketplace pools as "employers" under federal law, enabling them to offer group health coverage to members without discriminating based on health status. It requires these pools to provide uniform coverage to all members (including employees and dependents of participating employers), prohibit health-based enrollment barriers, and allow plans offering only prescription or over-the-counter drug coverage as a primary benefit. Key provisions include standardized pricing rules, geographic flexibility for pool operations, and clarifying that participation does not create employer or joint-employer relationships under other laws. The policy directly affects entities forming these pools (e.g., community cooperatives) and their members, such as small business employees and their dependents.
The Break Up Big Medicine Act requires large healthcare companies that own multiple parts of the healthcare system (such as insurance, pharmacies, and physician practices) to divest certain businesses to eliminate conflicts of interest. It prohibits common ownership between entities like health insurers and physician practices, or drug wholesalers and medical providers, mandating divestiture within one year of enactment. Non-compliance would trigger penalties including monthly escrow of 10% of profits, and the bill allows government agencies and individuals to sue for violations. This directly affects the largest health insurance companies, pharmacy benefit managers, and drug distributors that have integrated operations across the healthcare sector.
This bill expands Medicare coverage to include certain pharmacist services in medically underserved areas. It allows pharmacists licensed in their state to provide services that would otherwise be covered if done by a physician (like medication management), specifically in health professional shortage areas or medically underserved regions. Medicare would pay 80% of the physician fee schedule rate for these services, starting January 1, 2027. The bill requires the development of new billing codes for pharmacists under Medicare's physician fee schedule. It directly affects pharmacists working in designated underserved communities and Medicare beneficiaries there.
The PROTECT for Rare Act (S 3551) requires Medicare, Medicaid, and private health insurers to establish an expedited appeal process for coverage denials of drugs treating rare diseases or conditions affecting 200,000 or fewer U.S. individuals. It expands coverage criteria by allowing insurers to consider peer-reviewed medical literature and clinical guidelines - not just FDA-approved labeling - as valid justification for treatment, while excluding uses listed as contraindicated in approved drug labeling or medical references. The law applies to all covered drugs used for rare conditions and takes effect for coverage decisions starting January 1, 2027. This directly affects patients with rare diseases, healthcare providers seeking coverage approvals, and insurers managing drug benefit denials.
Treat and Reduce Obesity Act of 2025 This bill expands Medicare coverage of intensive behavioral therapy for obesity. Specifically, the bill allows coverage for therapy that is provided by (1) a physician who is not a primary care physician; or (2) other health care providers (e.g., physician assistants and nurse practitioners) and approved counseling programs, if provided upon a referral from, and in coordination with, a physician or primary care practitioner. Currently, such therapy is covered only if provided by a primary care practitioner. The bill also allows coverage under Medicare's prescription drug benefit of drugs used for the treatment of obesity or for weight loss management for individuals who are overweight.
